# OnCo record glioblastoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/glioblastoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "glioblastoma" ;
  schema:name "Glioma & glioblastoma"@en ;
  schema:description "Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma itself is the hardest to treat and has kept the same standard since 2005; CAR-T delivered into the brain and focused-ultrasound drug delivery are the live directions."@en ;
  schema:url <https://onco.cc/cancers/glioblastoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Glioblastoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q282142> ;
  schema:citation <https://en.wikipedia.org/wiki/Glioblastoma> ;
  onco:tag "cns", "spike" ;
  onco:related <https://onco.cc/roadmaps/cell-therapy-roadmap/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/collections/national-brain-tumor-society/>, <https://onco.cc/cancers/meningioma/>, <https://onco.cc/cancers/secondary-brain-tumours/>, <https://onco.cc/cancers/ependymoma/>, <https://onco.cc/cancers/medulloblastoma/> ;
  onco:technologies <https://onco.cc/technologies/ttfields/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/fluorescence-guided-surgery/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/hifu-histotripsy/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/bnct/>, <https://onco.cc/technologies/antineoplastons/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/litt/>, <https://onco.cc/technologies/bbb-focused-ultrasound/>, <https://onco.cc/technologies/glioma-car-t/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/shared-antigen-vaccine/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/hyperthermia/> ;
  onco:targets <https://onco.cc/targets/idh/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/b7h3/> ;
  onco:drugs <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/depatuxizumab-mafodotin/>, <https://onco.cc/drugs/neovax/> ;
  onco:companies <https://onco.cc/companies/philogen-s-p-a/>, <https://onco.cc/companies/neonc-technologies/>, <https://onco.cc/companies/aveta-biomics/>, <https://onco.cc/companies/hangzhou-hanx-biopharmaceuticals/>, <https://onco.cc/companies/servier/>, <https://onco.cc/companies/novocure/>, <https://onco.cc/companies/jazz/>, <https://onco.cc/companies/day-one-biopharmaceuticals/>, <https://onco.cc/companies/ipsen/>, <https://onco.cc/companies/insightec/>, <https://onco.cc/companies/northwest-biotherapeutics/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/curie-nki-eortc/> ;
  onco:institutions <https://onco.cc/institutions/city-of-hope/>, <https://onco.cc/institutions/stanford/>, <https://onco.cc/institutions/mgh/>, <https://onco.cc/institutions/penn-abramson/>, <https://onco.cc/institutions/heidelberg-nct/>, <https://onco.cc/institutions/dkfz/> ;
  onco:pathways <https://onco.cc/pathways/glioma-signalling/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/mgmt/>, <https://onco.cc/terms/h3k27m/>, <https://onco.cc/terms/egfrviii/>, <https://onco.cc/terms/blood-brain-barrier/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/accelerated-approval/>, <https://onco.cc/terms/re-irradiation/>, <https://onco.cc/terms/extent-of-resection/> ;
  onco:trials <https://onco.cc/trials/nct04250922/>, <https://onco.cc/trials/nct05118776/>, <https://onco.cc/trials/nct05303519/>, <https://onco.cc/trials/catnon/>, <https://onco.cc/trials/rtog-9402/>, <https://onco.cc/trials/eortc-26951/>, <https://onco.cc/trials/eortc-22033/>, <https://onco.cc/trials/nct07100730/>, <https://onco.cc/trials/nct06496971/>, <https://onco.cc/trials/nct05902169/>, <https://onco.cc/trials/nct05566795/>, <https://onco.cc/trials/nct07195591/>, <https://onco.cc/trials/nct06556563/>, <https://onco.cc/trials/intellance-1/>, <https://onco.cc/trials/eortc-26981/>, <https://onco.cc/trials/cctg-ce6/>, <https://onco.cc/trials/ef-14/>, <https://onco.cc/trials/indigo/>, <https://onco.cc/trials/checkmate-143/>, <https://onco.cc/trials/checkmate-498/>, <https://onco.cc/trials/checkmate-548/>, <https://onco.cc/trials/act-iv/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-singh-brain-tumour-initiating-cells-nature-2004/> ;
  onco:journals <https://onco.cc/journals/brain-tumor-pathology/>, <https://onco.cc/journals/cns-oncology/>, <https://onco.cc/journals/journal-of-neuro-oncology/> ;
  onco:pipeline <https://onco.cc/technologies/armored-car/>, <https://onco.cc/technologies/bnct/>, <https://onco.cc/technologies/hyperthermia/>, <https://onco.cc/drugs/lam561/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/drugs/asc40/>, <https://onco.cc/drugs/safusidenib/>, <https://onco.cc/drugs/ino-5401/>, <https://onco.cc/drugs/tng456/>, <https://onco.cc/drugs/bcb-276/>, <https://onco.cc/drugs/doc1021/>, <https://onco.cc/technologies/glioma-car-t/>, <https://onco.cc/technologies/bbb-focused-ultrasound/>, <https://onco.cc/technologies/litt/>, <https://onco.cc/drugs/dcvax-l/>, <https://onco.cc/drugs/dordaviprone/>, <https://onco.cc/drugs/tovorafenib/>, <https://onco.cc/ideas/idea-neoadjuvant-io-glioblastoma/>, <https://onco.cc/ideas/idea-fus-plus-adc-glioma/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/in-vivo-car-t/> ;
  onco:standardOfCare <https://onco.cc/technologies/fluorescence-guided-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/fluorescence-guided-surgery/>, <https://onco.cc/terms/extent-of-resection/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/trials/eortc-26981/>, <https://onco.cc/trials/cctg-ce6/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/trials/ef-14/>, <https://onco.cc/drugs/optune/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/mgmt/>, <https://onco.cc/trials/noa-08/>, <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/bevacizumab-glioma/>, <https://onco.cc/technologies/litt/>, <https://onco.cc/technologies/glioma-car-t/>, <https://onco.cc/technologies/bbb-focused-ultrasound/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/trials/indigo/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/dordaviprone/>, <https://onco.cc/technologies/glioma-car-t/>, <https://onco.cc/drugs/tovorafenib/> .